In pancreatic cancer cells, overexpression of integrin β1 activates the FAK/tyrosine kinase/Akt pathway, resulting in EGFR-independent cell proliferation and, as a result, the ability to overcome EGFR suppression by cetuximab [28]. The gene discussed is AKT1; the disease is pancreatic neoplasm.